Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical-stage medical device innovator advancing the Hemopurifier® - a therapeutic filtration device targeting cancer-enabling exosomes and life-threatening viruses. This page provides investors and medical professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.
Key resources include press releases detailing trial protocols, ethics committee approvals, and operational milestones. Users will find verified information on oncology applications for treatment-resistant cancers and infectious disease programs, all presented in compliance with financial disclosure standards.
Content highlights encompass FDA communications, trial enrollment updates, and peer-reviewed research collaborations. The curated news collection serves as a reliable reference for tracking the Hemopurifier®'s progress through clinical validation stages and potential therapeutic applications.
Bookmark this page for direct access to Aethlon Medical's official announcements, including breakthrough device designations and international trial expansions. Check regularly for updates on this pioneering approach to blood filtration technology and its implications for cancer immunotherapy advancement.
Aethlon Medical (NASDAQ: AEMD) reported its financial results for the third quarter ending December 31, 2022. The company continues developing the Hemopurifier®, focusing on cancer and life-threatening infectious diseases. A significant update includes a new oncology study set to initiate in Australia and the U.S. The company's cash balance stands at approximately $17.5 million, while operating expenses rose by 12% to roughly $2.85 million. Aethlon experienced a net loss of approximately $2.85 million, up from $2.53 million during the same period in 2021. The company did not record government contract revenue this quarter, impacting its financial results.
Aethlon Medical, Inc. (NASDAQ: AEMD) announced it will release its financial results for Q3 ended December 31, 2022, on February 6, 2023, at 4:15 p.m. EST. Following the results, a conference call will take place at 4:30 p.m. EST for management to discuss financial outcomes and corporate developments. The company focuses on developing the Hemopurifier, a clinical-stage device aimed at treating cancer and life-threatening infectious diseases. The Hemopurifier has received FDA Breakthrough Device designation due to its potential to remove harmful viruses and exosomes from blood.
FAQ
What is the current stock price of Aethlon Medical (AEMD)?
What is the market cap of Aethlon Medical (AEMD)?
